However, the failure of developing NFTs in APPNLGF x MAPT dKI mice highlights the challenges of naturally modeling tauopathy that aligns with clinical AD development chronologically, when tauopathy develops decades after amyloidosis. This evidence concerns the gene MAPT and Alzheimer disease.